1 citations
,
January 2025 in “Annals of Dermatology” Baricitinib is effective and safe for treating alopecia areata in Korea.
January 2026 in “Archivio istituzionale della ricerca (Alma Mater Studiorum Università di Bologna)” Baricitinib effectively promotes hair regrowth and improves well-being in severe alopecia areata patients.
January 2018 in “Journal of the American Academy of Dermatology” More extensive trials are needed to understand tofacitinib's role in treating severe hair loss.
Baricitinib showed mixed results in treating alopecia areata in children, with some improvement but also side effects.
January 2026 in “Dermatology and Therapy”
March 2024 in “International Journal of Dermatology” Baricitinib improved nail condition and hair regrowth in a patient with alopecia and nail abnormalities.
68 citations
,
April 2002 in “Journal of Alternative and Complementary Medicine” Natural 5AR inhibitors effectively improve mild to moderate hair loss in men.
2 citations
,
May 2017 in “Journal of the American Academy of Dermatology” Tofacitinib helped a 19-year-old regrow hair after other treatments failed.
2 citations
,
September 2024 in “PLoS ONE” Bendamustine combined with tucidinostat may effectively treat adult T-cell leukemia.
June 2025 in “The Journal of Dermatology” Baricitinib is effective and safe for long-term treatment of severe alopecia areata.
September 2022 in “Journal of The American Academy of Dermatology” Baricitinib was effective in regrowing eyebrow and eyelash hair in patients with severe alopecia areata.
July 2017 in “Nursing2023” Actemra is approved for a specific artery condition, HIV treatment adherence has improved, women may pay more for a hair loss product, and incorrect dosing of blood thinners can be risky.
June 2024 in “Poster presentations” Janus Kinase inhibitors effectively induce remission in Ulcerative Colitis with an acceptable safety profile.
64 citations
,
August 2019 in “Circulation” ADT, especially enzalutamide, may increase the risk of heart rhythm problems and sudden death in men.
September 2025 in “Value in Health” January 2026 in “Medicina” JAK inhibitors show promise for treating various skin disorders effectively and safely.
August 2023 in “Frontiers in Oncology” New drugs and therapies targeting specific pathways show promise in treating advanced prostate cancer.
September 2022 in “PubMed” Entadfi, a mix of finasteride and tadalafil, is used for BPH.
2 citations
,
February 2024 in “Indian Dermatology Online Journal” Tofacitinib effectively improved hair regrowth and skin condition in a woman with alopecia totalis and lichen planus hypertrophicus.
June 2025 in “BMJ Case Reports” Axitinib treatment turned a man's grey hair back to black.
31 citations
,
January 2017 in “Advances in Experimental Medicine and Biology” Low testosterone and 5α-reductase inhibitors can harm men's metabolic and sexual health; testosterone therapy may help, but discussing 5α-RIs' side effects is important.
4 citations
,
December 2024 in “Clinical Cosmetic and Investigational Dermatology” Combining baricitinib with UV-B therapy effectively treats non-segmental vitiligo and is well-tolerated.
March 2026 in “Immunological Medicine” Janus kinase inhibitors help some people with severe alopecia areata regrow hair, but not everyone responds, and relapses can happen.
60 citations
,
August 2022 in “ESMO Open” Trastuzumab deruxtecan is effective for HER2-positive breast cancer but requires careful management of side effects.
November 2024 in “SKIN The Journal of Cutaneous Medicine” Baricitinib slightly increased cholesterol levels in alopecia areata patients, but these changes were manageable.
December 2025 in “PubMed” Baricitinib is effective and safe for treating severe alopecia areata.
7 citations
,
January 2025 in “Journal of Experimental & Clinical Cancer Research” PRMT5 inhibitors effectively fight adenoid cystic carcinoma in salivary glands.
1 citations
,
May 2017 in “Journal of the American Academy of Dermatology” Oral tofacitinib may be an effective and tolerable treatment for some people with severe alopecia areata.
February 2025 in “PubMed” Switching JAK inhibitors can lead to significant hair regrowth in severe alopecia cases.
4 citations
,
September 2022 in “Journal of The American Academy of Dermatology” Baricitinib was effective in regrowing hair in patients with different levels of alopecia areata severity.